Navigation Links
Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
Date:6/29/2012

THE WOODLANDS, Texas, June 29, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today the publication of results from two initial trials of LX4211 in patients with type 2 diabetes in the online edition of the journal Clinical Pharmacology & Therapeutics. The paper, containing results from both trials, is entitled, "LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients with Type 2 Diabetes in a Randomized, Placebo-controlled Trial," and will also appear in an upcoming print edition of the journal. A link to the online article can be accessed at http://www.nature.com/clpt/journal/vaop/ncurrent/full/clpt201258a.html.

"This publication represents the first peer-reviewed description of SGLT1 inhibition stimulating GLP-1 and PYY release in man," said Dr. Brian Zambrowicz, Lexicon's executive vice president and chief scientific officer. "Since LX4211 also inhibits SGLT2, the rapid and significant glycemic control and metabolic benefits observed may be attributed to effective dual inhibition of these two targets."

In the 4-week Phase 2a study described in the paper, 36 patients received once-daily oral administration of placebo or 150 mg or 300 mg of LX4211 (randomized 1:1:1) in an in-patient setting. Patients receiving LX4211 exhibited rapid and significant improvements relative to placebo in multiple measures of glycemic control, including hemoglobin A1c (HbA1c), fasting plasma glucose, and oral glucose tolerance. In addition, serum triglycerides were significantly lower at the end of the four-week treatment period, and trends of meaningful reductions in body weight an
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
2. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
3. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
4. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
5. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
6. Lexicon to Provide First Quarter 2012 Financial Results
7. Medivir Announces an Interferon-Free Phase II Combination Trial With TMC435 and daclatasvir to Commence Shortly
8. Hanger, Inc. Announces Second Quarter 2012 Earnings Release Conference Call
9. ResMed Announces Conference Call And Webcast To Discuss Fourth Quarter And Fiscal Year-End 2012 Results
10. Marshall Edwards Announces Name Change to MEI Pharma ("MEIP")
11. Access Pharmaceuticals Announces Positive Data From MuGard Phase 4 Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
(Date:9/16/2014)... -- Russia,s pharmaceutical ... Pharma 2020 Strategy provides incentives for local producers to ... foreign markets. These trends, however, were affected by recent ... political and economic sanctions imposed on Russia ... Russia responded to the US ...
(Date:9/16/2014)... Sept. 16, 2014 Surgeons at The Children,s ... a case report the first successful use of a ... year-old boy with failing Fontan circulation to bridge him ... 3 years old, the patient received a Fontan circulation ... single ventricle. "The Fontan operation is the final planned ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4Global Medicines for Russia 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 3
... and PRINCETON, N.J., Jan. 31, 2011 Qforma, the leading ... health sciences industry, today announced the appointments of Ted Pine ... Michael Murphy as Software Engineer. "As Qforma ... optimize service to our pharmaceutical industry customers, we welcome the ...
... 2011 OXIS International, Inc., (OTC Bulletin Board: ... favorable final results from an initial clinical study to ... joint health formula, launched commercially in December 2010. ... statistically significant after as little as one week of ...
Cached Medicine Technology:Qforma, Leading Provider of Healthcare Analytics, Announces Three New Appointments 2Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 2Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 3Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 4
(Date:9/16/2014)... hold great promise in helping people to reach ... devices help the wearers improve their wellness by ... information is organized into companion computer programs and ... quickly growing market for these devices, researchers at ... analyzed 13 of these activity monitors, such as ...
(Date:9/16/2014)... 16, 2014 (HealthDay News) -- Although magnesium sulfate is ... preterm delivery, new research suggests it won,t provide any ... effects of magnesium sulfate given to pregnant women, researchers ... behavioral, growth or functional outcomes among those children when ... old. The new findings don,t negate the fact ...
(Date:9/16/2014)... radiation therapy as part of breast conservation is ... hormone-receptor positive (HR+) invasive breast cancer. A new ... however, shows that combination may not be necessary ... , The results, which Fox Chase researchers presented ... Annual Meeting on Sunday, September 14, suggest that ...
(Date:9/16/2014)... September 16, 2014 Programs and policies ... hundreds of billions of dollars in savings for the ... the Commonwealth Fund. To help spur these types of ... to 10 collaborative groups from across the country to ... http://bit.ly/1wo4gsa ) - a handbook designed to assist groups ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Who:, The ... Anschutz Medical Campus and Children’s Hospital Colorado ... is the country’s leading pulmonary hypertension association that works to ... a disease of the lungs that affects the functioning of ... treatment, mean survivability is only 2.8 years. , What:, ...
Breaking Medicine News(10 mins):Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3Health News:Researchers Don't See Long-Term Benefits From Drug for Preemies 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:NQF Seeks Field Testing Groups for Population Health Guide 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 3Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2
... June 30 Standard & Poor,s will make the,following changes ... the,close of trading on Wednesday, July 2:, -- S&P ... replace Getty Images Inc. (NYSE: GYI ) in the ... replace IDEXX Laboratories in the S&P,SmallCap 600. Getty Images is ...
... findings as fact , , MONDAY, June 30 (HealthDay News) -- ... HDL cholesterol and loss of memory. , The study, which has ... percent increased loss of memory on a word test for those ... with the highest levels. By age 60, the rate of memory ...
... than placebo, one expert says , , MONDAY, June 30 ... of placing intravenous (IV) lines in children, Canadian researchers ... by 34 percent in children getting IV lines when ... rate of inserting the lines, said lead researcher Dr. ...
... for two adults? Experts consider this question alongside new ... Liver Transplantation , a journal by John Wiley ... Wiley Interscience ( www.interscience.wiley.com ). , The shortage of ... increase opportunities for those in need of a transplant. ...
... researchers at the Ocean University of China has developed and ... can accurately measure wind speed and direction over large areas ... weather forecasting and sports. , As described in the ... published by the Optical Society, the mobile lidar station can ...
... June 30 Robbins & Myers, Inc.,(NYSE: RBN ... for the third quarter,results conference call scheduled today, June ... or 1-617-614-3525,with ID# 84552408. Replays of the call can ... # 63192398., Robbins & Myers, Inc. is a ...
Cached Medicine News:Health News:Standard & Poor's Announces Changes to U.S. Indices 2Health News:Standard & Poor's Announces Changes to U.S. Indices 3Health News:Research Links Low HDL Levels With Memory Loss 2Health News:Spray Cuts Kids' Pain When Getting IVs 2Health News:Experts examine challenges of split liver transplantation 2Health News:New technology may help Olympic sailing 2
19 Gauge. Reusable. Block of 4 each....
18 gauge curved. Fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
Set consist of two 23 gauge, stainless steel probes with blunt tips. Probes are 18 cm (7.0 inches) long with 30.5 cm (12 inches) of flexible tubing (O.D. - 0.60 mm, I.D. - 0.30 mm) attached onto the ...
Curved, soft flexible tip allows atraumatic entry through a retinal tear or hole for aspiration of subretinal fluids. 20 gauge x 25 mm cannula attached to 25 gauge x 6 mm tip with 13 mm flexible tubi...
Medicine Products: